5 Top Reasons the Pharmacy Calls You And How to Avoid Them

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Dupilumab was associated with the highest drug survival in monotherapy with nearly 90% of study participants remaining on treatment at both 12 and 24 months.

Keith A. Reynolds

October 1st 2024

Ruxolitinib Cream 1.5% Demonstrates Efficacy in Prurigo Nodularis: Phase 3 Findings

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Data from the TRuE-PN trial program were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, offering important insights into potential new therapeutic options for this debilitating condition.

October 25th 2023

Icotrokinra Shows Promise for Moderate-to-Severe Plaque Psoriasis in Phase 3 Trials

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Tapinarof Cream 1% Demonstrates Sustained Disease Control in Adults, Children with Atopic Dermatitis

Icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor, which is implicated in multiple inflammatory conditions including plaque psoriasis.

Dupilumab Demonstrates Superior Long-Term Persistence Over Upadacitinib and Tralokinumab in Atopic Dermatitis

AAD 2025: New analysis of the ADORING 3 trial showed tapinarof maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.

Related Content

Grace Halsey

March 9th 2025

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Dupilumab was associated with the highest drug survival in monotherapy with nearly 90% of study participants remaining on treatment at both 12 and 24 months.

Keith A. Reynolds

October 1st 2024

Ruxolitinib Cream 1.5% Demonstrates Efficacy in Prurigo Nodularis: Phase 3 Findings

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

October 25th 2023

Icotrokinra Shows Promise for Moderate-to-Severe Plaque Psoriasis in Phase 3 Trials

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Tapinarof Cream 1% Demonstrates Sustained Disease Control in Adults, Children with Atopic Dermatitis

Icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor, which is implicated in multiple inflammatory conditions including plaque psoriasis.